<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prescribing epinephrine for anaphylaxis self-treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prescribing epinephrine for anaphylaxis self-treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prescribing epinephrine for anaphylaxis self-treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott H Sicherer, MD, FAAAAI</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John M Kelso, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">Epinephrine</a> is the drug of choice in the treatment of anaphylaxis and is available in many parts of the world in the form of epinephrine autoinjectors for self-treatment [<a href="#rid1">1,2</a>]. However, when prescribing these devices, clinicians must teach patients how and when to use them and dispel fears about adverse effects. Autoinjectors may be lifesaving for patients but only if patients are willing and able to use these devices effectively. All of the current devices used for self-administration of epinephrine are designed for intramuscular injection. Studies are underway regarding alternative routes not requiring injection such as intranasal, sublingual, and inhaled [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H2"><span class="h1">PHARMACOLOGY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">Epinephrine</a> is a sympathomimetic agent with multiple actions that can reverse the symptoms of anaphylaxis. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Beneficial effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">Epinephrine</a> acts as an agonist at alpha-1 receptors to mediate increased vasoconstriction, increased peripheral vascular resistance, and decreased mucosal edema. Agonist effects at beta-2 receptors result in bronchodilation and decreased mediator release from mast cells and basophils  (<a class="graphic graphic_table graphicRef65684" href="/d/graphic/65684.html" rel="external">table 1</a>) [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Even when injected properly, <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> is often associated with minor and transient adverse effects such as tremor, dizziness, palpitations, anxiety, restlessness, and headache  (<a class="graphic graphic_table graphicRef65684" href="/d/graphic/65684.html" rel="external">table 1</a>) [<a href="#rid4">4</a>].</p><p>In contrast, serious adverse effects such as myocardial ischemia are rare after injection of a 0.3 mg dose in an adult or a 0.15 mg dose in a child. Such effects occur more commonly with <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> overdose, especially after intravenous administration. Reluctance to administer epinephrine due to fear of adverse cardiac effects should be countered by the awareness that myocardial ischemia and dysrhythmias can also occur in children and adults with anaphylaxis who have not received epinephrine treatment and in whom no cardiovascular disease can be found after the episode [<a href="#rid5">5,6</a>].</p><p class="headingAnchor" id="H5"><span class="h3">Unintentional injections and other injuries</span><span class="headingEndMark"> — </span>The rate of unintentional injections of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> from autoinjectors is high [<a href="#rid7">7,8</a>], with more than 15,000 such events being reported voluntarily to the American Association of Poison Control Centers from 1994 to 2007 [<a href="#rid8">8</a>]. A systematic review of 69 unintentional injections found that 91 percent involved a finger or thumb [<a href="#rid7">7</a>]. In another large retrospective series of 365 unintentional injections specifically to the hand, all patients had complete resolution of symptoms without the need for admission or surgery [<a href="#rid9">9</a>]. In this series, warm water soaks alone were used in 32 percent, and no drug therapy was administered in 77 percent. In 23 percent, various vasodilatory therapies were given (including topical <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> paste or local injection[s] of <a class="drug drug_general" data-topicid="9767" href="/d/drug information/9767.html" rel="external">phentolamine</a>). Most patients had resolution of symptoms within two hours.</p><p>Other injuries related to use of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> autoinjectors include lacerations, embedded needles, and injection site infections (<em>Clostridium perfringens</em>) [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span>There are no absolute contraindications to the administration of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> for anaphylaxis [<a href="#rid1">1,2</a>]. Therefore, all patients who have experienced anaphylaxis should have access to epinephrine for self-treatment, including pregnant patients at risk and patients who may be at greater risk for serious adverse effects, such as older individuals with cardiovascular disease.</p><p class="headingAnchor" id="H7"><span class="h1">AVAILABLE DEVICES</span></p><p class="headingAnchor" id="H8"><span class="h2">Autoinjectors</span><span class="headingEndMark"> — </span>The following preloaded <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> autoinjectors are available in the United States:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>EpiPen (brand name)</strong> – Containing 0.3 mg per dose</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>EpiPen Jr (brand name)</strong> – Containing 0.15 mg per dose</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Authorized generics of EpiPen</strong> – Containing 0.3 or 0.15 mg per dose</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Authorized generics of Adrenaclick</strong> – Containing 0.3 or 0.15 mg per dose (brand name no longer available)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Auvi-Q (brand name; Allerject [brand name] in Canada) </strong>– Containing 0.3 mg, 0.15 mg, or 0.1 mg per dose (provides audible directions to guide user)</p><p></p><p>In Canada (and Europe among others) another device, the Emerade autoinjector, is available as 0.15 mg, 0.3 mg, and 0.5 mg.</p><p class="headingAnchor" id="H501329"><span class="h3">Availability and cost</span><span class="headingEndMark"> — </span>Depending on the country, other brands of autoinjectors, generic autoinjectors, and prefilled, sealed syringes containing <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> are available. It is important that prefilled syringes be sealed, since epinephrine in unsealed syringes degrades rapidly [<a href="#rid11">11</a>]. Cost may also be an issue in some health systems. A study using a commercial insurance database in the United States found that with the advent of generic devices, most patients paid $20, although about 1 in 13 paid over $200 [<a href="#rid12">12</a>].</p><p>Differences in the design and use of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> self-injection products available need to be considered in the context of patient skills and preferences [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H2667814504"><span class="h2">Prefilled syringes</span><span class="headingEndMark"> — </span>A prefilled syringe (Symjepi [brand name]) containing 0.15 mg or 0.3 mg of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> per dose was approved by the US Food and Drug Administration and should offer a more affordable alternative to autoinjectors. The 0.15 mg dose is labeled for patients 15 to 30 kg (33 to 66 lbs), and the 0.3 mg dose is labeled for patients ≥30 kg (66 lbs). The medication is contained in a light-blocking plastic case, and patients must remove the needle cap, insert the needle into the anterolateral thigh, and depress the plunger to dispense the dose.</p><p>The prescription of ampules of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> and a syringe as a low-cost alternative has been discussed, but this approach suffers from potential dosing errors when used by laypersons in an emergency [<a href="#rid14">14</a>]. The provision of a syringe prefilled with epinephrine, stored away from light and kept for a brief period such as three months, has also been considered as a low-cost alternative but suffers from concerns about sterility and stability [<a href="#rid15">15</a>]. These options may be more suited to resource-poor regions.</p><p class="headingAnchor" id="H502244"><span class="h3">Training</span><span class="headingEndMark"> — </span>We suggest designating the specific name and description of the product intended to be dispensed on the prescription order and providing patient education that is specific to that product. Training devices that do not contain needles or <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> are available to clinicians and patients from the manufacturers in most cases and are sometimes dispensed at the pharmacy when the patient fills the prescription. In addition, manufacturers provide detailed instructions and videos online. Studies suggest that recurrent training may be required [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H501778"><span class="h2">Number of doses to dispense</span><span class="headingEndMark"> — </span>There are no global consensus guidelines about how many autoinjectors should be dispensed for each patient [<a href="#rid2">2</a>]. Decision-making might include past reaction history, risk of severe anaphylaxis, access to additional care, and other factors. Many allergy specialists prescribe at least two for all patients, and some prescribe more. The following should be considered:</p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review and meta-analysis that included 86 studies found that 7.7 percent of anaphylaxis cases from any cause were treated with more than 1 dose of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>. Considering epinephrine-treated reactions where the subsequent doses were administered by heath care professionals, the rate was 11 percent for food allergy and 17 percent for venom allergy [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is a theoretical concern that overweight or obese teenagers and adults may be underdosed (on a per kg basis) when treated with the 0.3 mg autoinjector, although this has not been proven [<a href="#rid4">4,18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The distance between the patient's home/work/school and the nearest medical facility also impacts the number of doses that should be available to the patient. The World Health Organization (WHO) and Anaphylaxis Canada recommend the availability of one dose for every 10 to 20 minutes of travel time to a medical emergency facility [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concerns about overprescribing additional units and generating excessive cost have been raised [<a href="#rid20">20</a>]. As an example, having multiple units available at school for each at-risk child when many units are already available in the school for other children may not be necessary [<a href="#rid21">21</a>].</p><p></p><p class="headingAnchor" id="H501394"><span class="h1">DOSING</span><span class="headingEndMark"> — </span>In North America, several brands of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> autoinjectors are available in doses of 0.15 mg and 0.3 mg. One brand (Auvi-Q) also has a dose of 0.1 mg available, which is labeled for use in infants and toddlers 7.5 to 15 kg (16.5 to 33 lbs) [<a href="#rid22">22</a>]. The 0.15 mg dose is labelled for those weighing 15 to 30 kg (33 to 66 lbs). The 0.3 mg dose is labelled for adults and children weighing ≥30 kg (66 lbs). Large or obese individuals should have access to multiple doses. Dosing in small children is discussed below. (See <a class="local">'Small children'</a> below.)</p><p class="headingAnchor" id="H501591"><span class="h2">Adults</span><span class="headingEndMark"> — </span>Autoinjectors with 0.3 mg of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> per dose are appropriate for adults.</p><p class="headingAnchor" id="H501597"><span class="h3">Large or obese adults</span><span class="headingEndMark"> — </span>Very large or obese adults should have access to at least two doses of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>.</p><p>In patients with significant adipose tissue on the anterolateral thigh, the needle of an <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> autoinjector may not be of sufficient length to reach the underlying muscle, and compression of the tissue during injection is minimal. Compared with subcutaneous injection, intramuscular injection of epinephrine results in higher and more rapid plasma concentrations and is therefore the recommended route of delivery [<a href="#rid23">23</a>]. However, in a series of 28 patients, needle length was not sufficient to reach the underlying muscle of the anterolateral thigh in 68 percent of patients [<a href="#rid24">24</a>]. The issue was more common in females, even those with normal body mass index (BMI). These findings may raise concerns about suboptimal delivery, although human treatment studies have not been undertaken to quantify the potential differences in serum dose and kinetics. In addition, a retrospective chart review of emergency department patients with anaphylaxis, mostly children, found that the need for a second dose did not correlate with overweight status, suggesting repeat dosing is not a result of obesity or suboptimal medication delivery [<a href="#rid18">18</a>]. Having a second autoinjector available addresses the concern that treatment may be inadequate for this or other reasons, pending further study of the implications of needle length and patient weight.</p><p class="headingAnchor" id="H9"><span class="h2">Children</span><span class="headingEndMark"> — </span>In most countries, <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> autoinjectors are available in only two fixed doses: 0.15 mg and 0.3 mg. One manufacturer has developed a 0.1 mg dose (Auvi-Q [brand name]). The availability of specific doses in autoinjectable form presents difficulties in delivering an appropriate dose to many children. The recommended dose of epinephrine for children is 0.01 mg/kg, up to 0.3 mg. Therefore, the premeasured autoinjectors technically contain the recommended dose only for a 10 kg (22 lbs), 15 kg (33 lbs) or a 30 kg (66 lbs) individual.</p><p class="headingAnchor" id="H10"><span class="h3">Small children</span><span class="headingEndMark"> — </span>The prescribing information for autoinjectors containing 0.15 mg of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> indicates that the dose is intended for patients weighing 15 to 30 kg (33 to 66 lbs). Using these manufacturers' guidelines, children weighing 25 kg (55 lbs) would receive the 0.15 mg dose, although the optimal dose for a child of that weight is higher (0.25 mg). Furthermore, little information is provided about dosing in a child weighing less than 15 kg (33 lbs), other than the caveat that dosing decisions are the responsibility of the prescribing clinician.</p><p>Examples of dosing issues raised by fixed-dose autoinjectors in infants and small children include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>For a 7.5 kg (16.5 lbs) child</strong> – The 0.1 mg autoinjector delivers 133 percent of the ideal dose, and the 0.15 mg autoinjector delivers 200 percent of the ideal dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For a 10 kg (22 lbs) child</strong> – The 0.15 mg autoinjector delivers 150 percent of the ideal dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For a 12.5 kg (27.5 lbs) child</strong> – The 0.1 mg dose delivers only 80 percent of the ideal dose, while the 0.15 mg autoinjector delivers 120 percent of the ideal dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For a 20 kg (44 lbs) child</strong> – The 0.15 mg autoinjector delivers only 75 percent of the ideal dose, while the 0.3 mg autoinjector delivers 150 percent of the ideal dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For a 25 kg (55 lbs) child</strong> – The 0.15 mg autoinjector delivers only 60 percent of the ideal dose, while the 0.3 mg autoinjector delivers 120 percent of the ideal dose.</p><p></p><p>Despite the lack of precision in dosing with autoinjectors, the alternative (ie, drawing up <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> in a syringe to obtain the correct weight-based dose) is associated with delayed administration, inaccurate dosing, and potential loss of the dose. A study of the ability of parents without medical training to utilize an ampule and syringe after receiving verbal and written instructions in a nonurgent setting found this method to be error-prone and slow [<a href="#rid14">14</a>].</p><p>One study indicated that children generally tolerate higher doses of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> without serious adverse events. In a randomized trial, children (aged four to eight years and weighing 15 to 30 kg [33 to 66 lbs]) who were at risk for anaphylaxis received either 0.15 mg or 0.3 mg of epinephrine intramuscularly [<a href="#rid25">25</a>]. The higher dose resulted in significantly higher systolic blood pressures compared with the lower dose but was also associated with transient nausea, palpitations, and headache.</p><p class="headingAnchor" id="H4155465548"><span class="h4">Suggested approach</span><span class="headingEndMark"> — </span>To provide additional guidance to the clinician, a clinical report from the American Academy of Pediatrics reviewed the risks and benefits of selecting the 0.15 mg or the 0.3 mg fixed doses for children of different weights [<a href="#rid26">26</a>]. The report references European guidelines, suggesting the 0.15 mg autoinjector may be used for infants weighing as little as 7.5 kg (16.5 lbs) [<a href="#rid27">27</a>]. Subsequent to this report, the 0.1 mg Auvi-Q (brand name) became available in some countries and is labeled for use in infants and toddlers 7.5 to 15 kg (16.5 to 33 lbs). The following summarizes our suggested approach based on these guidelines, but specific decisions should be individualized according to patient characteristics and caretaker preferences (eg, severity of allergy, comorbid conditions, cost/availability of autoinjectors, caretaker proficiency with using a syringe and ampule)  (<a class="graphic graphic_table graphicRef139665" href="/d/graphic/139665.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef139666" href="/d/graphic/139666.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Ideal dosing for infants under 7.5 kg (16.5 lbs) would require an ampule and syringe or a prefilled syringe. The 0.1 mg autoinjector (only available as Auvi-Q [brand name]) could also be considered for infants near the upper end of this weight range if an autoinjector is believed to have important benefits over other delivery devices.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For infants/children weighing 7.5 to 10 kg (16.5 to 22 lbs), the clinician has the following prescribing option:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prescribe a 0.1 mg (ideal) or a 0.15 mg autoinjector (option if the 0.1 mg autoinjector is not accessible).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For infants/children weighing 10 kg (22 lbs) up to 15 kg (33 lbs), either the 0.1 mg (matches manufacturer labeling but only one product available) or 0.15 mg autoinjector is appropriate. However, as noted above, use of the 0.1 mg dose becomes less ideal as the child approaches 15 kg.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When the 0.1 mg autoinjector is an option, the American Academy of Pediatrics suggests using this device from 7.5 kg (16.6 lbs) to less than 13 kg (28.6 lbs) [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children weighing 15 kg (33 lbs) to less than 25 kg (55 lbs) can receive the 0.15 mg dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children weighing 25 kg or more (55 lbs or more) can receive the 0.3 mg dose autoinjector.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dosing might be individualized for children with severe past reactions, to select the higher of the two fixed doses at lower weights.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In Canada where the 0.5 mg Emerade device is available, the manufacturer suggests using this for adults &gt;60 kg, and a Canadian position statement suggested this be prescribed for those weighing 45 kg (99 lbs) or more [<a href="#rid29">29</a>].</p><p></p><p class="headingAnchor" id="H13"><span class="h1">KEY TEACHING POINTS</span><span class="headingEndMark"> — </span>There are several important teaching points that should be emphasized when instructing patients in optimal use of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> autoinjectors. These should be reviewed with patients at regular intervals. Patient information that reiterates these teaching points is also available. (See <a class="local">'Information for patients'</a> below.)</p><p class="headingAnchor" id="H14"><span class="h2">Anaphylaxis is unpredictable</span><span class="headingEndMark"> — </span>Patients should understand that anaphylaxis is highly unpredictable [<a href="#rid30">30</a>]. One exposure to an allergen may result in mild symptoms, while the next causes a life-threatening reaction or vice versa, for reasons that are not fully understood.</p><p class="headingAnchor" id="H15"><span class="h2">Epinephrine is the best treatment available</span><span class="headingEndMark"> — </span>The patient should be assured that <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> is the most effective treatment available for anaphylaxis and that having an autoinjector will enable the patient to start treatment without delay. Fatal anaphylaxis is associated with lack of availability of epinephrine or failure to inject epinephrine promptly [<a href="#rid31">31,32</a>]. This fact may be expressed to the patient as the following: "In most cases of anaphylaxis that prove fatal, the person who died either did not have epinephrine available or had it available but did not use it. Thus, by having an epinephrine autoinjector and knowing how to use it, the patient already has a significant advantage."</p><p class="headingAnchor" id="H16"><span class="h2">Carry the autoinjector at all times</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">Epinephrine</a> autoinjectors must be carried at all times in order to be available when the drug is actually needed. Patients may make the mistake of having their autoinjectors on hand only in the setting where they spend most time (ie, home, school, or work). However, they may be at particular risk for anaphylaxis when out of their normal routines (eg, during exercise, while dining out, attending celebrations and banquets, or traveling). Thus, patients should devise a way for an autoinjector to be available at all times. This may mean storing autoinjectors in multiple locations or carrying a small bag containing the autoinjector and other essential items that is taken everywhere, without exception.</p><p class="headingAnchor" id="H17"><span class="h2">Antihistamines or asthma inhalers are not sufficient treatment for anaphylaxis</span><span class="headingEndMark"> — </span>Patients must understand that antihistamines and inhaled beta-agonists can treat some symptoms of allergic reactions (urticaria, pruritus, and bronchospasm, respectively), but they cannot reverse laryngeal edema or hypotension and are too slow-acting to be effective in rapidly developing anaphylaxis  (<a class="graphic graphic_table graphicRef65684" href="/d/graphic/65684.html" rel="external">table 1</a>) [<a href="#rid1">1,2</a>].</p><p>Antihistamines and asthma inhalers alone may appear to adequately control symptoms in anaphylaxis in some instances, but it is unclear if improvement is due to the medications or the patient's own corrective physiologic responses. Therefore, clinicians and patients must regard <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> as the first and best treatment for anaphylaxis.</p><p class="headingAnchor" id="H18"><span class="h2">When to use it</span><span class="headingEndMark"> — </span>Clinicians should use plain language to explain to patients when to self-administer <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>. In the setting of an allergic reaction, patients should use the epinephrine autoinjector <strong>immediately</strong> if they:</p><p class="bulletIndent1"><span class="glyph">●</span>Are having trouble breathing</p><p class="bulletIndent1"><span class="glyph">●</span>Feel tightness in the throat</p><p class="bulletIndent1"><span class="glyph">●</span>Feel lightheaded or think they might pass out</p><p></p><p>If treating a child with an allergic reaction, <strong>also</strong> use the autoinjector if the child:</p><p class="bulletIndent1"><span class="glyph">●</span>Is not responding as expected or has altered consciousness during an allergic reaction</p><p class="bulletIndent1"><span class="glyph">●</span>Has food allergies and is vomiting repeatedly shortly after eating, especially if accompanied by flushing or hives</p><p class="bulletIndent1"><span class="glyph">●</span>Is coughing repeatedly during an allergic reaction (indicating bronchospasm)</p><p class="bulletIndent1"><span class="glyph">●</span>Had previous anaphylaxis and develops widespread hives after a suspected or known ingestion of the allergen</p><p class="bulletIndent1"><span class="glyph">●</span>Has definitely eaten a trigger food that previously caused severe anaphylaxis and is having any symptoms [<a href="#rid33">33,34</a>]</p><p></p><p class="headingAnchor" id="H19"><span class="h2">How to use it</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">Epinephrine</a> should ideally be injected into the mid-outer part of the thigh, into the underlying muscle. Intramuscular injection is preferable to subcutaneous injection, as it results in more rapid systemic absorption [<a href="#rid23">23,30</a>]. Patients should be instructed to hold the device with a closed fist (ie, like a baton, with thumb/fingers away from either end) as accidental injection of the thumb/fingers or palm can occur if the autoinjector is inverted [<a href="#rid7">7</a>]. Children may not hold still for an injection, and caregivers should hold the child's leg firmly in place. The autoinjector should be held in place for at least three seconds after the injection. Instructions for different devices suggest 3 to 10 seconds, although most of the medicine is released from the device within the first second [<a href="#rid35">35</a>].</p><p>Patients should be instructed to stay with other people if possible during an allergic reaction. There is no need to undress before using the autoinjector, as the needles are designed to penetrate clothing. However, we typically instruct patients to raise skirts or lower pants, if possible, to avoid an obstruction such as a buckle or contents of a pocket.</p><p>The clinician should demonstrate how to use the specific autoinjector that is being prescribed, by using the specific training device for that autoinjector. Detailed written instructions are provided separately (see <a class="local">'Information for patients'</a> below). Manufacturers also provide DVDs and videos on their websites.</p><p class="headingAnchor" id="H20"><span class="h2">Use it without delay</span><span class="headingEndMark"> — </span>Patients should understand that <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> is most effective when given within the first few minutes of an allergic reaction.</p><p class="headingAnchor" id="H21"><span class="h2">Call for help and go to the emergency department</span><span class="headingEndMark"> — </span>If the patient is alone, <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> should be self-administered first and then the patient should call for help and be transported to the nearest emergency department (ED) as soon as possible in case the symptoms of anaphylaxis worsen or recur without further exposure to the trigger. It is important to make clear to patients that the reason for proceeding to the emergency department is the possibility of worsening or recurrent symptoms. Some patients misinterpret instructions to go to the emergency department as evidence that epinephrine is dangerous and that they must be examined whenever they have self-administered it. This, in turn, can cause them to avoid use of the autoinjector.</p><p>During the early part of the coronavirus disease 2019 (COVID-19) pandemic, with infectious risks increased for ED visits, the necessity of transport to the ED for all episodes of allergic reactions treated with <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> was questioned [<a href="#rid36">36</a>]. Indeed, most reactions respond to one dose of epinephrine and do not require additional treatment. However, a decision not to proceed to an ED could also carry serious risks should the symptoms worsen and require additional interventions. Provider advice regarding home management should be individualized, and we favor having the patient proceed to an ED. It may be reasonable to have home management under circumstances such as close proximity to an ED, confidence in patient self-assessments, prompt and excellent response to treatment, access to additional autoinjectors and comfort with use, and patient circumstances (such as past reactions being mild/self-limited, not having significant asthma, etc). Circumstances that would argue against home management include any reluctance to treat, lack of autoinjectors, patient not being comfortable, past serious reactions, etc. These considerations are not an exhaustive list and ultimately such decisions would need to be made in communication with a health care provider.</p><p>Even if the emergency department is in close proximity or emergency medical services are en route, the <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> autoinjector should still be administered.</p><p>If patients become lightheaded, they should lie down with their legs elevated, if possible, in order to increase blood flow to vital organs. Similarly, if the patient loses consciousness in the caregiver's presence, the patient should be placed on their back with legs elevated.</p><p>Patients should never be propped up during anaphylaxis. Rising to an upright position during severe anaphylaxis has been associated with sudden death due to the "empty ventricle syndrome" [<a href="#rid37">37</a>]. Patients should be transported to an emergency medical facility in the supine position.</p><p class="headingAnchor" id="H22"><span class="h2">More than one dose may be needed</span><span class="headingEndMark"> — </span>Patients should be advised that a second dose may be needed if symptoms do not appear to be stabilizing or improving, and this may be given 5 to 15 minutes after the first dose [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H23"><span class="h2">Practice with the training device</span><span class="headingEndMark"> — </span>Autoinjectors are dispensed with a training device that is identical to the autoinjector but does not contain a needle or medication. Patients/caregivers should practice periodically with a training device. They should also use the trainer to teach others who may need to administer the <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> if the patient is incapacitated. They should also be warned that the actual/live device may have more recoil than the trainer and they should be prepared for this and continue to hold the device firmly against the thigh [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H24"><span class="h2">Teach others</span><span class="headingEndMark"> — </span>Patients should be encouraged to inform and educate appropriate friends, caretakers, colleagues, and food providers about their allergic condition. It may be essential that those around them are able to recognize an allergic reaction and react effectively, both by administering <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> and calling for assistance if the patient is incapacitated.</p><p>Patients and caregivers should use the training devices to teach others how to administer <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>. (See  <a class="medical medical_review" href="/d/html/5739.html" rel="external">"Food allergy in schools and camps"</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Replace the autoinjectors prior to expiration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">Epinephrine</a> autoinjectors have a limited shelf life and should be replaced prior to expiration. Some patients renew their prescription on their birthday or at the start of the calendar year in order to link renewal to an annual event.</p><p>Autoinjectors have a window to inspect for discoloration of the solution or precipitated material in the solution, which are signs that the solution is losing potency. However, ideally, expired autoinjectors should also be replaced, even if the solution remains clear.</p><p class="headingAnchor" id="H3716679951"><span class="h2">Use of expired autoinjectors</span><span class="headingEndMark"> — </span>Patients should be informed that it is preferable to use an out-of-date autoinjector rather than not injecting <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> at all [<a href="#rid39">39</a>]. At least three studies have found that expired autoinjectors retain significant potency, even up to four years after the expiration date:</p><p class="bulletIndent1"><span class="glyph">●</span>One study found that <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> solutions that were within 24 months of their expiration dates still contained at least 90 percent of the labeled dose [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study found that among 31 expired autoinjectors, those less than 12 months past expiration contained 88 to 100 percent of the intended dose, and the oldest (50 months past expiration) contained 84 to 88 percent of the intended dose [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study that measured the active enantiomer found that 65 percent of devices retained &gt;90 percent of activity over almost two years [<a href="#rid42">42</a>]. The 0.3 mg devices maintained potency better than the 0.15 mg devices: within 36 months post expiration, 93 percent of adult devices and 66 percent of pediatric devices retained &gt;90 percent potency.</p><p></p><p class="headingAnchor" id="H26"><span class="h2">Storage</span><span class="headingEndMark"> — </span>Patients should be instructed to keep <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> autoinjectors or prefilled syringes in locations with neutral temperatures (waist pack, purse, cabinets) rather than locations where the unit may overheat or freeze (glove compartment of a car, in an uninsulated bag on the beach). The devices should not be refrigerated.</p><p class="bulletIndent1"><span class="glyph">●</span>Freezing and thawing appears to be better tolerated than storage at excessively hot temperatures [<a href="#rid43">43-45</a>]. A study examined the effects of storage of nine EpiPens for 12 hours in various locations inside a car on a summer day and found that temperatures within the car reached as high as 62°C (143°F; highest in the glove compartment) and that this single exposure resulted in decrements of 3 to 14 percent in the concentration of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, without changes in the appearance of the solution [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Based on limited data and information from the US Food and Drug Administration, autoinjectors are unlikely to be adversely affected by radiograph equipment at airport security [<a href="#rid47">47,48</a>].</p><p></p><p class="headingAnchor" id="H27"><span class="h1">AREAS OF UNCERTAINTY FOR THE PRESCRIBING CLINICIAN</span><span class="headingEndMark"> — </span>There are several areas of uncertainty for prescribing <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> and teaching patients about when it is appropriate to inject the medication. These situations require clinical judgment.</p><p class="headingAnchor" id="H28"><span class="h2">Who is at risk for anaphylaxis?</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">Epinephrine</a> is indicated for persons who have experienced anaphylaxis to an agent they may encounter again, and for patients with idiopathic anaphylaxis. However, there may be less obvious circumstances where prescribing epinephrine is also appropriate [<a href="#rid2">2,49,50</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>It may be unclear from the clinical history whether anaphylaxis occurred and clinical judgment may be needed to decide whether it did occur.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An individual may have experienced a mild reaction to an allergen that is known to cause severe reactions (eg, a peanut/tree nut allergy). As an example, it would be reasonable to prescribe <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> for a child with severe eczema who was found to have peanut allergy and placed on a peanut-free diet but who had displayed only flares of eczema after eating peanut and never had a more serious reaction. Such patients may be at risk for anaphylaxis if subsequently exposed to the culprit allergen [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An individual may have had an allergic reaction with clinical features that may indicate a higher risk of anaphylaxis on a future exposure, such as reactions to trace amounts of a food.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There may be comorbid diseases or medications that increase the risk for a severe reaction, such as asthma or the use of beta-blockers.</p><p></p><p class="headingAnchor" id="H29"><span class="h3">Oral allergy syndrome</span><span class="headingEndMark"> — </span>The risk of a systemic reaction in a patient with oral allergy syndrome and the relative indications for prescription of self-injectable <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> are reviewed separately. (See  <a class="medical medical_review" href="/d/html/2407.html" rel="external">"Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)", section on 'Indications for epinephrine'</a>.)</p><p class="headingAnchor" id="H30"><span class="h2">Instructing patients when to inject epinephrine</span><span class="headingEndMark"> — </span>Certain symptom combinations, particularly with known or likely exposure to an allergen, are indications to inject <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, as reviewed above [<a href="#rid34">34</a>]. However, there are circumstances where it may be appropriate to instruct patients to self-inject when such symptoms have <strong>not</strong> occurred or are mild:</p><p class="bulletIndent1"><span class="glyph">●</span>If symptoms are mild but the patient is in a remote location.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the symptoms are mild but the reaction appears to be progressing rapidly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient or caregiver is uncertain about the severity of the reaction, in which case it is preferable to administer <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> rather than withhold it.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If there has been a known ingestion of a food or an insect sting that previously caused a severe reaction, and any symptoms develop.</p><p></p><p>Knowledge about the nature of the exposure is also helpful in deciding whether to inject <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>.</p><p class="bulletIndent1"><span class="glyph">●</span>For example, if it is known that a food allergen was rubbed into the eye but definitely not ingested, then progression to anaphylaxis is unlikely and symptoms such as eyelid angioedema would not be a reason to inject <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>. However, if the allergen was definitely ingested, the victim had a history of severe anaphylaxis to the same trigger, and eyelid angioedema was noted, it would be reasonable to inject epinephrine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A child with asthma and an upper respiratory infection who ate a presumably safe meal and then exercised and developed severe wheezing is not likely experiencing anaphylaxis but rather an asthma exacerbation and would warrant inhaled bronchodilator therapy. In contrast, a child with severe asthma and peanut allergy who ate a peanut cookie and developed severe wheezing would warrant injection with <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>.</p><p></p><p class="headingAnchor" id="H4973413"><span class="h2">Responsibilities of older children and adolescents</span><span class="headingEndMark"> — </span>As children at risk for anaphylaxis mature, they need to become responsible for recognizing and treating anaphylaxis. In an online survey of 88 pediatric allergists, participants were asked about the age at which children are able to begin assuming these responsibilities [<a href="#rid52">52</a>]. These allergists most frequently responded that children aged 9 to 11 years should be able to describe some symptoms of anaphylaxis, recognize the need for <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, and demonstrate correct use of an autoinjector. By age 12 to 14 years, most allergists expected children to take some responsibility for self-administering epinephrine when needed. They individualized the timing based on assessment of patient readiness factors, including medical history, developmental level, and ability to demonstrate correct autoinjector technique. It is important to note that a similar survey of parents and caregivers indicated that these individuals perceived the transition period as roughly three years earlier than the allergists, indicating the need to discuss whether children are capable of taking on these responsibilities on an individual basis [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H4103122112"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/105526.html" rel="external">"Society guideline links: Anaphylaxis"</a>.)</p><p class="headingAnchor" id="H31"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15917.html" rel="external">"Patient education: How to use an epinephrine autoinjector (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/365.html" rel="external">"Patient education: Using an epinephrine autoinjector (Beyond the Basics)"</a>)</p><p></p><p>For patients with diagnosed anaphylaxis, three key steps include prescription of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, patient education, and follow-up evaluation [<a href="#rid30">30</a>]. Epinephrine should always be prescribed in the context of a comprehensive care plan, including instructions on allergen avoidance, as well as indications for injection of epinephrine and instructions on activating additional emergency services (eg, calling 911).</p><p class="headingAnchor" id="H3035374071"><span class="h2">Printable action plans</span><span class="headingEndMark"> — </span>Printable action plans are available from multiple sources:</p><p class="bulletIndent1"><span class="glyph">●</span>The American Academy of Allergy, Asthma, and Immunology has devised an "Anaphylaxis Emergency Action Plan" (available in <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.aaaai.org%2FAaaai%2Fmedia%2FMediaLibrary%2FPDF+Documents%2FLibraries%2FAnaphylaxis-Emergency-Action-Plan.pdf&amp;token=%2FC5Q%2FiCB%2F2LLCwV7T8HK2lwm6sR%2FkEZoNaIqN%2F73HXSOVycSIPyputPn68SH00rxz4XgltVFJ9rSmMATkiTNtTCeVQHr44rjlSZkcJVXEDbh%2Bx3d7qqBZUqDAak3uoXk%2FI0U9CKYd1MPL7MRKdB8kw%3D%3D&amp;TOPIC_ID=388" target="_blank">English</a> and <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.aaaai.org%2FAaaai%2Fmedia%2FMediaLibrary%2FPDF+Documents%2FSpanish%2FAnaphylaxis-Emergency-Action-Plan-Spanish.pdf&amp;token=Ls%2BBUTXwAuTJRkpRQ4LA1JgGv03onx4w09YFWrjDcTMb8nQK70M4sv3yKBB6Ojk%2FBSHuni4YwWs1wy9vgRTN0JU2OPH9WbcbiuH8WjlQ7CNVIxv%2FGWSD5R2OrOOaPAI%2FdBm3AtkXm1l5Bk3m72nDvg%3D%3D&amp;TOPIC_ID=388" target="_blank">Spanish</a>) that can be personalized and provided to any patient who has experienced anaphylaxis. This plan provides clear instructions for patients about how to treat an anaphylaxis episode and gives both the clinician and the patient an opportunity to personalize the instructions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Action plans specific to children are also available  (<a class="graphic graphic_form graphicRef118732" href="/d/graphic/118732.html" rel="external">form 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Versions of action plans designed specifically for patients with food allergy are available from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.foodallergy.org%2F&amp;token=oN6rXOmeBLkIpfIsq5mH5XowUrwo9JF1Bee2tadnAs8nOz4ixcAr6ReEsd5sotUp&amp;TOPIC_ID=388" target="_blank">Food Allergy Research and Education (FARE) website</a>.</p><p></p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duties of clinician</strong> – When prescribing <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> autoinjectors for anaphylaxis self-treatment, clinicians must also provide patient-specific advice about when and how to administer epinephrine and dispel fears about its adverse effects. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacology of </strong><a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> – Epinephrine is a sympathomimetic agent with multiple actions that can reverse the symptoms of anaphylaxis  (<a class="graphic graphic_table graphicRef65684" href="/d/graphic/65684.html" rel="external">table 1</a>). (See <a class="local">'Pharmacology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Safety</strong> – <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">Epinephrine</a> will cause transient and minor adverse effects in most patients, even when used properly. However, patients should be reassured that serious adverse effects, such as myocardial ischemia, are rare with the doses delivered by an autoinjector. Furthermore, untreated anaphylaxis itself is associated with myocardial ischemia and dysrhythmias. Thus, all patients with past anaphylaxis should have access to epinephrine for self-treatment. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Available devices</strong> – Several different autoinjector devices are available, which vary in ease of use and cost. Prefilled, sealed syringes containing <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> are another option that is more commonly used in resource-limited settings. Once a device is selected, we suggest designating the specific name and description of the product on the prescription order and providing patient education that is specific to that product. (See <a class="local">'Available devices'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing of autoinjectors</strong> – Most <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> autoinjectors are available in doses of 0.15 mg and 0.3 mg. One manufacturer produces a device for infants that contains 0.1 mg  (<a class="graphic graphic_table graphicRef139665" href="/d/graphic/139665.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef139666" href="/d/graphic/139666.html" rel="external">table 3</a>). The manufacturer's labelled dosing ranges differ from some expert opinions reflected here.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The 0.3 mg dose is appropriate for children and adults weighing 25 kg or more (55 lbs or more). Large or obese individuals should have access to multiple doses. (See <a class="local">'Dosing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dosing in young children and infants is more difficult, as the available doses result in doses either below or above the ideal dose for many. The 0.15 mg dose may be used for children between 10 and up to 25 kg (22 to &lt;55 lbs) if the 0.1 mg dose is not available. If the 0.1 mg autoinjector is available, the switch to the 0.15 mg dose could be at 13 kg (28.6 lbs). (See <a class="local">'Children'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For infants and small children weighing 7.5 kg (16.5 lbs) to &lt;13 kg (&lt;28.6 lbs), the 0.1 mg dose is ideal, but the 0.15 mg dose can be prescribed if the 0.1 mg dose is unavailable. (See <a class="local">'Small children'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Teaching points</strong> – There are several important teaching points that should be emphasized when instructing patients in optimal use of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> autoinjectors, which address most patients' areas of concern and confusion. This information should be reviewed with patients at regular intervals. (See <a class="local">'Key teaching points'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Issues requiring clinical judgement</strong> – Clinical situations arise in which it is not clear if <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> should be injected. As an example, it is reasonable to instruct a patient with severe anaphylaxis to food who subsequently had a known ingestion of the culprit food to inject epinephrine even before any symptoms have developed. (See <a class="local">'Areas of uncertainty for the prescribing clinician'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol 2020; 145:1082.</a></li><li><a class="nounderline abstract_t">Muraro A, Worm M, Alviani C, et al. EAACI guidelines: Anaphylaxis (2021 update). Allergy 2022; 77:357.</a></li><li><a class="nounderline abstract_t">Boswell B, Rudders SA, Brown JC. Emerging Therapies in Anaphylaxis: Alternatives to Intramuscular Administration of Epinephrine. Curr Allergy Asthma Rep 2021; 21:18.</a></li><li><a class="nounderline abstract_t">Simons KJ, Simons FE. Epinephrine and its use in anaphylaxis: current issues. Curr Opin Allergy Clin Immunol 2010; 10:354.</a></li><li><a class="nounderline abstract_t">Triggiani M, Patella V, Staiano RI, et al. Allergy and the cardiovascular system. Clin Exp Immunol 2008; 153 Suppl 1:7.</a></li><li><a class="nounderline abstract_t">Kounis NG. Kounis syndrome (allergic angina and allergic myocardial infarction): a natural paradigm? Int J Cardiol 2006; 110:7.</a></li><li><a class="nounderline abstract_t">Simons FE, Lieberman PL, Read EJ Jr, Edwards ES. Hazards of unintentional injection of epinephrine from autoinjectors: a systematic review. Ann Allergy Asthma Immunol 2009; 102:282.</a></li><li><a class="nounderline abstract_t">Simons FE, Edwards ES, Read EJ Jr, et al. Voluntarily reported unintentional injections from epinephrine auto-injectors. J Allergy Clin Immunol 2010; 125:419.</a></li><li><a class="nounderline abstract_t">Muck AE, Bebarta VS, Borys DJ, Morgan DL. Six years of epinephrine digital injections: absence of significant local or systemic effects. Ann Emerg Med 2010; 56:270.</a></li><li><a class="nounderline abstract_t">Brown JC, Tuuri RE, Akhter S, et al. Lacerations and Embedded Needles Caused by Epinephrine Autoinjector Use in Children. Ann Emerg Med 2016; 67:307.</a></li><li><a class="nounderline abstract_t">Rawas-Qalaji M, Simons FE, Collins D, Simons KJ. Long-term stability of epinephrine dispensed in unsealed syringes for the first-aid treatment of anaphylaxis. Ann Allergy Asthma Immunol 2009; 102:500.</a></li><li><a class="nounderline abstract_t">Chua KP, Conti RM. Out-of-Pocket Spending on Epinephrine Auto-Injectors Among the Privately Insured, 2015-2019. J Gen Intern Med 2023; 38:538.</a></li><li><a class="nounderline abstract_t">Camargo CA Jr, Guana A, Wang S, Simons FE. Auvi-Q versus EpiPen: preferences of adults, caregivers, and children. J Allergy Clin Immunol Pract 2013; 1:266.</a></li><li><a class="nounderline abstract_t">Simons FE, Chan ES, Gu X, Simons KJ. Epinephrine for the out-of-hospital (first-aid) treatment of anaphylaxis in infants: is the ampule/syringe/needle method practical? J Allergy Clin Immunol 2001; 108:1040.</a></li><li><a class="nounderline abstract_t">Pepper AN, Westermann-Clark E, Lockey RF. The High Cost of Epinephrine Autoinjectors and Possible Alternatives. J Allergy Clin Immunol Pract 2017; 5:665.</a></li><li><a class="nounderline abstract_t">Umasunthar T, Procktor A, Hodes M, et al. Patients' ability to treat anaphylaxis using adrenaline autoinjectors: a randomized controlled trial. Allergy 2015; 70:855.</a></li><li><a class="nounderline abstract_t">Patel N, Chong KW, Yip AYG, et al. Use of multiple epinephrine doses in anaphylaxis: A systematic review and meta-analysis. J Allergy Clin Immunol 2021; 148:1307.</a></li><li><a class="nounderline abstract_t">Rudders SA, Geyer BC, Banerji A, et al. Obesity is not a risk factor for repeat epinephrine use in the treatment of anaphylaxis. J Allergy Clin Immunol 2012; 130:1216.</a></li><li class="breakAll">The website address for Anaphylaxis Canada is www.anaphylaxis.org (Accessed on February 04, 2011).</li><li><a class="nounderline abstract_t">Shaker M, Turner PJ, Greenhawt M. A Cost-Effectiveness Analysis of Epinephrine Autoinjector Risk Stratification for Patients with Food Allergy-One Epinephrine Autoinjector or Two? J Allergy Clin Immunol Pract 2021; 9:2440.</a></li><li><a class="nounderline abstract_t">Norton L, Dunn Galvin A, Hourihane JO. Allergy rescue medication in schools: modeling a new approach. J Allergy Clin Immunol 2008; 122:209.</a></li><li class="breakAll">Prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201739s008s009lbl.pdf (Accessed on May 03, 2018).</li><li><a class="nounderline abstract_t">Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol 2001; 108:871.</a></li><li><a class="nounderline abstract_t">Johnstone J, Hobbins S, Parekh D, O'Hickey S. Excess subcutaneous tissue may preclude intramuscular delivery when using adrenaline autoinjectors in patients with anaphylaxis. Allergy 2015; 70:703.</a></li><li><a class="nounderline abstract_t">Simons FE, Gu X, Silver NA, Simons KJ. EpiPen Jr versus EpiPen in young children weighing 15 to 30 kg at risk for anaphylaxis. J Allergy Clin Immunol 2002; 109:171.</a></li><li><a class="nounderline abstract_t">Sicherer SH, Simons FER, SECTION ON ALLERGY AND IMMUNOLOGY. Epinephrine for First-aid Management of Anaphylaxis. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Muraro A, Roberts G, Worm M, et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy 2014; 69:1026.</a></li><li class="breakAll">American Academy of Pediatrics. Allergy and Anaphylaxis Emergency Plan. https://downloads.aap.org/HC/AAP_Allergy_and_Anaphylaxis_Emergency_Plan.pdf (Accessed on August 25, 2022).</li><li><a class="nounderline abstract_t">Li LDX, Abrams EM, Lavine E, et al. CSACI position statement: transition recommendations on existing epinephrine autoinjectors. Allergy Asthma Clin Immunol 2021; 17:130.</a></li><li><a class="nounderline abstract_t">Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.</a></li><li><a class="nounderline abstract_t">Bock SA, Muñoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol 2007; 119:1016.</a></li><li><a class="nounderline abstract_t">Pumphrey RS, Gowland MH. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol 2007; 119:1018.</a></li><li><a class="nounderline abstract_t">Turner PJ, DunnGalvin A, Hourihane JO. The Emperor Has No Symptoms: The Risks of a Blanket Approach to Using Epinephrine Autoinjectors for All Allergic Reactions. J Allergy Clin Immunol Pract 2016; 4:1143.</a></li><li><a class="nounderline abstract_t">Wang J, Sicherer SH, SECTION ON ALLERGY AND IMMUNOLOGY. Guidance on Completing a Written Allergy and Anaphylaxis Emergency Plan. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Baker TW, Webber CM, Stolfi A, Gonzalez-Reyes E. The TEN study: time epinephrine needs to reach muscle. Ann Allergy Asthma Immunol 2011; 107:235.</a></li><li><a class="nounderline abstract_t">Casale TB, Wang J, Oppenheimer J, Nowak-Wegrzyn A. Acute At-Home Management of Anaphylaxis: 911: What Is the Emergency? J Allergy Clin Immunol Pract 2022; 10:2274.</a></li><li><a class="nounderline abstract_t">Pumphrey RS. Fatal posture in anaphylactic shock. J Allergy Clin Immunol 2003; 112:451.</a></li><li><a class="nounderline abstract_t">Jacobsen RC, Guess TM, Burks AW. Comparing activation and recoil forces generated by epinephrine autoinjectors and their training devices. J Allergy Clin Immunol 2012; 129:1143.</a></li><li><a class="nounderline abstract_t">Simons FE, Gu X, Simons KJ. Outdated EpiPen and EpiPen Jr autoinjectors: past their prime? J Allergy Clin Immunol 2000; 105:1025.</a></li><li><a class="nounderline abstract_t">Rachid O, Simons FE, Wein MB, et al. Epinephrine doses contained in outdated epinephrine auto-injectors collected in a Florida allergy practice. Ann Allergy Asthma Immunol 2015; 114:354.</a></li><li><a class="nounderline abstract_t">Cantrell FL, Cantrell P, Wen A, Gerona R. Epinephrine Concentrations in EpiPens After the Expiration Date. Ann Intern Med 2017; 166:918.</a></li><li><a class="nounderline abstract_t">Kassel L, Jones C, Turin R, et al. Enantiomeric degradation of epinephrine in autoinjector products. J Allergy Clin Immunol Pract 2022; 10:2463.</a></li><li><a class="nounderline abstract_t">Rachid O, Simons FE, Rawas-Qalaji M, et al. Epinephrine doses delivered from auto-injectors stored at excessively high temperatures. Drug Dev Ind Pharm 2016; 42:131.</a></li><li><a class="nounderline abstract_t">Rachid O, Simons FE, Rawas-Qalaji M, et al. Epinephrine autoinjectors: does freezing or refrigeration affect epinephrine dose delivery and enantiomeric purity? J Allergy Clin Immunol Pract 2015; 3:294.</a></li><li><a class="nounderline abstract_t">Parish HG, Bowser CS, Morton JR, Brown JC. A systematic review of epinephrine degradation with exposure to excessive heat or cold. Ann Allergy Asthma Immunol 2016; 117:79.</a></li><li><a class="nounderline abstract_t">Lacwik P, Bialas AJ, Wielanek M, et al. Single, short-time exposure to heat in a car during sunny day can decrease epinephrine concentration in autoinjectors: a real-life pilot study. J Allergy Clin Immunol Pract 2019; 7:1362.</a></li><li><a class="nounderline abstract_t">Sullivan DJ, Hubbard LB, Broadbent MV, et al. The effect of ionizing radiation on advanced life support medications. Ann Emerg Med 1987; 16:662.</a></li><li class="breakAll">US Food and Drug Administration. Frequently Asked Questions on Cabinet X-ray Systems. http://www.fda.gov/Radiation-EmittingProducts/RadiationEmittingProductsandProcedures/SecuritySystems/ucm116421.htm (Accessed on August 25, 2022).</li><li><a class="nounderline abstract_t">Sicherer SH, Simons FE, Section on Allergy and Immunology, American Academy of Pediatrics. Self-injectable epinephrine for first-aid management of anaphylaxis. Pediatrics 2007; 119:638.</a></li><li><a class="nounderline abstract_t">Sicherer SH, Simons FE. Quandaries in prescribing an emergency action plan and self-injectable epinephrine for first-aid management of anaphylaxis in the community. J Allergy Clin Immunol 2005; 115:575.</a></li><li><a class="nounderline abstract_t">Nachshon L, Goldberg MR, Elizur A, et al. Food allergy to previously tolerated foods: Course and patient characteristics. Ann Allergy Asthma Immunol 2018; 121:77.</a></li><li><a class="nounderline abstract_t">Simons E, Sicherer SH, Simons FE. Timing the transfer of responsibilities for anaphylaxis recognition and use of an epinephrine auto-injector from adults to children and teenagers: pediatric allergists' perspective. Ann Allergy Asthma Immunol 2012; 108:321.</a></li><li><a class="nounderline abstract_t">Simons E, Sicherer SH, Weiss C, Simons FE. Caregivers' perspectives on timing the transfer of responsibilities for anaphylaxis recognition and treatment from adults to children and teenagers. J Allergy Clin Immunol Pract 2013; 1:309.</a></li></ol></div><div id="topicVersionRevision">Topic 388 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32001253" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34343358" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : EAACI guidelines: Anaphylaxis (2021 update).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33666759" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Emerging Therapies in Anaphylaxis: Alternatives to Intramuscular Administration of Epinephrine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20543673" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epinephrine and its use in anaphylaxis: current issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18721322" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Allergy and the cardiovascular system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16249041" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Kounis syndrome (allergic angina and allergic myocardial infarction): a natural paradigm?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19441598" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hazards of unintentional injection of epinephrine from autoinjectors: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159254" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Voluntarily reported unintentional injections from epinephrine auto-injectors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20346537" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Six years of epinephrine digital injections: absence of significant local or systemic effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26452720" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Lacerations and Embedded Needles Caused by Epinephrine Autoinjector Use in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19558009" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Long-term stability of epinephrine dispensed in unsealed syringes for the first-aid treatment of anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35819685" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Out-of-Pocket Spending on Epinephrine Auto-Injectors Among the Privately Insured, 2015-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24565484" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Auvi-Q versus EpiPen: preferences of adults, caregivers, and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11742286" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Epinephrine for the out-of-hospital (first-aid) treatment of anaphylaxis in infants: is the ampule/syringe/needle method practical?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28215605" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The High Cost of Epinephrine Autoinjectors and Possible Alternatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25850463" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Patients' ability to treat anaphylaxis using adrenaline autoinjectors: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33862009" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Use of multiple epinephrine doses in anaphylaxis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23021879" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Obesity is not a risk factor for repeat epinephrine use in the treatment of anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23021879" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Obesity is not a risk factor for repeat epinephrine use in the treatment of anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33486143" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A Cost-Effectiveness Analysis of Epinephrine Autoinjector Risk Stratification for Patients with Food Allergy-One Epinephrine Autoinjector or Two?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18538380" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Allergy rescue medication in schools: modeling a new approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18538380" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Allergy rescue medication in schools: modeling a new approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11692118" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Epinephrine absorption in adults: intramuscular versus subcutaneous injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25676800" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Excess subcutaneous tissue may preclude intramuscular delivery when using adrenaline autoinjectors in patients with anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11799385" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : EpiPen Jr versus EpiPen in young children weighing 15 to 30 kg at risk for anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28193791" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Epinephrine for First-aid Management of Anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24909803" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24909803" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34903280" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : CSACI position statement: transition recommendations on existing epinephrine autoinjectors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461139" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17306354" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Further fatalities caused by anaphylactic reactions to food, 2001-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17349682" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Further fatal allergic reactions to food in the United Kingdom, 1999-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27283056" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The Emperor Has No Symptoms: The Risks of a Blanket Approach to Using Epinephrine Autoinjectors for All Allergic Reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28193793" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Guidance on Completing a Written Allergy and Anaphylaxis Emergency Plan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21875542" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The TEN study: time epinephrine needs to reach muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35569813" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Acute At-Home Management of Anaphylaxis: 911: What Is the Emergency?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12897756" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Fatal posture in anaphylactic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22078473" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparing activation and recoil forces generated by epinephrine autoinjectors and their training devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10808186" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Outdated EpiPen and EpiPen Jr autoinjectors: past their prime?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25707326" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Epinephrine doses contained in outdated epinephrine auto-injectors collected in a Florida allergy practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28492859" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Epinephrine Concentrations in EpiPens After the Expiration Date.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35640791" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Enantiomeric degradation of epinephrine in autoinjector products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25997362" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Epinephrine doses delivered from auto-injectors stored at excessively high temperatures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25609348" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Epinephrine autoinjectors: does freezing or refrigeration affect epinephrine dose delivery and enantiomeric purity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27221065" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A systematic review of epinephrine degradation with exposure to excessive heat or cold.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30503198" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Single, short-time exposure to heat in a car during sunny day can decrease epinephrine concentration in autoinjectors: a real-life pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3578971" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The effect of ionizing radiation on advanced life support medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3578971" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The effect of ionizing radiation on advanced life support medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17332221" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Self-injectable epinephrine for first-aid management of anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15753907" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Quandaries in prescribing an emergency action plan and self-injectable epinephrine for first-aid management of anaphylaxis in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29684569" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Food allergy to previously tolerated foods: Course and patient characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22541402" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Timing the transfer of responsibilities for anaphylaxis recognition and use of an epinephrine auto-injector from adults to children and teenagers: pediatric allergists' perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24565494" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Caregivers' perspectives on timing the transfer of responsibilities for anaphylaxis recognition and treatment from adults to children and teenagers.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
